Axsome Therapeutics, Inc. Stock News

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and conference call today at 8:00 AM Eastern Time to discuss the U.S. Food and Drug Administration (FDA) approval of SYMBRAVO®, a novel multi-mechanistic approach to trea...

The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.

A single oral dose of SYMBRAVO provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours

Axsome Therapeutics shows strong revenue growth from Auvelity and Sunosi, with promising late-stage pipeline drugs for migraine, fibromyalgia, and narcolepsy. Late-stage pipeline milestones include AXS-07 for migraine (PDUFA: January 31, 2025), AXS-12 for narcolepsy, and AXS-14 for fibromyalgia. Despite mixed Phase 3 results for AXS-05 in Alzheimer's agitation, the overall data is favorable, su...

Shares of Axsome Therapeutics dropped Monday on mixed test results for its Alzheimer's disease agitation treatment. The post Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation appeared first on Investor's Business Daily.

Axsome Therapeutics said on Monday its experimental treatment for the Alzheimer's disease-related agitation met the main goal of a late-stage trial.

ACCORD-2 Phase 3 trial in Alzheimer's disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse)

Axsome's AXS-12 met its primary endpoint in a Phase 3 study, significantly reducing cataplexy attacks in narcolepsy patients, positioning it for an NDA submission. The narcolepsy market is substantial, with current treatments having issues like tolerability and efficacy, which AXS-12 aims to address effectively. Financially, Axsome has a market cap of $4.83bn, strong revenue growth, but a net l...